Cytomegalovirus (CMV) infection in patients receiving either alemtuzumab (CAMPATH 1-H) or antithymocyte globulin (ATG) as graft-versus-host disease (GVHD) prophylaxis prior to allogeneic stem cell transplantation (SCT)  by Hunt, W.G. et al.
donor). Complete donor whole blood (WB) chimerism (unsorted
peripheral blood) was achieved in 7 of 11 pts by D  14, while 4
pts had mixed chimerism (30%, 69%, 88%, 95% donor). D  14
WB chimerism results were comparable to adult pts (13/18 com-
plete, 5 mixed-65%, 95%, 95%, 95%, 95% donor). There was a
trend towards a greater degree of mixed chimerism in younger pts
and those with less pre-transplant immune depletion. Conclu-
sions: Rapid, complete donor engraftment and chimerism can be
achieved in pediatric pts with cancer using a NM alloSCT regi-
men. Pre-transplant immune depletion appears to be somewhat
more difﬁcult to achieve compared to adult pts, particularly in
regard to CD8 T cells. Intensive immune depletion might be
required to consistently achieve rapid complete donor chimerism
in pediatric pts undergoing NM alloSCT.
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CYTOMEGALOVIRUS (CMV) INFECTION IN PATIENTS RECEIVING EI-
THER ALEMTUZUMAB (CAMPATH 1-H) OR ANTITHYMOCYTE GLOBU-
LIN (ATG) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS
PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION (SCT)
Hunt, W.G.1,2, May, G.R.4, Krance, R.A.2,3, Heslop, H.E.2,3,4, Cathe-
rine, B.2,3, Kuehnle, I.2,3 1. Department of Pediatrics, Section of Pedi-
atric Infectious Diseases, Texas Children’s Hospital, Baylor College of
Medicine, Houston, TX; 2. Department of Pediatrics, Center for Cell and
Gene Therapy, Texas Children’s Hospital, Baylor College of Medicine,
Houston, TX; 3. Department of Pediatrics, Texas Children’s Cancer
Center, Texas Children’s Hospital, Baylor College of Medicine, Houston,
TX; 4. Center for Cell and Gene Therapy, The Methodist Hospital,
Houston, TX.
The potential of anti-leukocyte antibodies to decrease GVHD in
allogeneic SCT recipients has lead to inclusion of these antibodies
in chemotherapeutic regimens, some of which have been associated
with increased CMV infection in adults despite antiviral therapy.
To determine the effect of Campath 1-H or ATG on CMV
infection in nonmyeloablative or myeloablative regimens in pedi-
atric patients, we compared the retrospective incidence of CMV
infection and disease in 105 pediatric SCT recipients at Texas
Childrens Hospital over ﬁve years, from April 1998 throughMarch
2002. Eighty-four of the 105 patients had either seropositive donor
or recipient status, and all received either ganciclovir or foscarnet
prophylaxis. CMV antigenemia, polymerase chain reaction (PCR),
or buffy coat culture were monitored weekly for the ﬁrst 120 days
and subsequently as needed. CMV reactivation appeared similar
with Campath 1-H, 22/37 (59%), and ATG, 24/47 (51%, P  .5,
Power  80) and also was similar with the myeloablative and
nonmyeloablative groups, 39/70 (56%) and 7/14 (50%, P  .8),
respectively. There was a trend towards higher CMV reactivation
during the ﬁrst 120 days with Campath 1-H versus ATG, 21/37
(59%) in comparison to 17/47 (36%, P  .06), but this was not
statistically signiﬁcant. The incidence of CMV recurrence was
similar among all groups tested, as was the occurrence of GVHD.
Although there was a trend towards earlier CMV reactivation in
patients receiving Campath, disease was not more frequent, likely
associated with an increase in ganciclovir or change to foscarnet
upon positive CMV surveillance. One patient given Campath/
myeloablation and two receiving ATG/myeloablation had CMV
disease. A trend towards an increase in CMV reactivation during
the ﬁrst 100 days with Campath versus ATG likely reﬂects that
Campath depletes more cell lines than ATG, and this effect di-
minishes with engraftment. In summary, Campath 1-H was not
associated with a higher risk of CMV reactivation but was associ-
ated with earlier CMV reactivation without an increase in disease
compared to ATG. We are currently initiating a study evaluating
if adoptive immunotherapy with donor-derived CMV-speciﬁc cy-
totoxic T cells can reconstitute immunity to CMV and reduce the
rate of reactivation.
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MATCHED AND MISMATCHED UNRELATED CORD BLOOD (UCB) STEM
CELL TRANSPLANT (SCT) IN ADULTS: PRELIMINARY RESULTS OF AN
ONGOING PROSPECTIVE TRIAL
Chen, W., Stives, S., Visweshwar, N., Diaz, B., Yanbeiy, N., Ojha, R.,
Saad, M., Parumog, N., Farley, T., Nath, R. St. Joseph’s Regional
Medical Center, Paterson, NJ.
UCB has been commonly used as a source of allogeneic stem
cells in infants and children who lack a suitable HLA-matched
sibling donor. However, the success of UCB-SCT in adults is
limited by lower number of stem cells in cord blood which results
in delayed and reduced overall incidence of engraftment.
8 patients have been treated at SJRMC since August 2002. Di-
agnosis at transplant include MDS/AML (2), ALL (2), Burkitt
Lymphoma (1), HD (1), NHL (2). 6/8 patients had active disease,
1 had PhALL in 3rd remission, and 1 had testicular lymphoma
with history of bone marrow involvement in 2nd remission. 2 had
received prior radiation to the lungs/mediastinum. The median age
was 52 years (range 29-60). The median weight was 86 kg (range
66-104). 7 out of 8 patients were CMV seropositive.
All patients were uniformly conditioned with Thiotepa (10
mg/kg day–7), Busulfan (3.2 mg/kg day –6 to –4), Cyclophosph-
amide (60 mg/kg day –3 to –2), Anti-thymocyte globulin (20 mg/kg
day –4 and –2), and high dose Solu-medrol (500mg IV day –4 and
–2). GVHD prophylaxis consisted of Mycophenolate Mofetil (IV/
PO, day –1 to  56) and Tacrolimus (levels 5-20 ng/ml from day
–1). HLA match was 6/6 in one case, and 4/6 in seven cases based
on intermediate resolution matching on class I loci and high
resolution matching on class II loci. The median total nucleated
cell (TNC) dose based on pre-cryopreserved sample was 2.57
(range 1.88-3.96) x107/kg. Patients were infused a median of 1.99
(range 0.81-5.68) x 107 TNC/kg and 0.96 (range 0.70-2.50) x 105
CD34 cells/kg. All 8 patients engrafted. The median time to
ANC 200/l, 500/l, and 1000/l was day 22 (range 17-30), day
24 (range 20-35), and day 26 (range 23-38), respectively. The
median time to platelet count  20 x 109/l for 6 patients was day
64 (range 47 to156), and 50 x 109/l for 3 patients was day 170
(range 56-172). All 8 patients survived day 100. All 8 patients
achieved 100% donor chimerism on day 30. 7/8 had 100% donor
chimerism on day 100. 1 patient had 90% donor chimerism on day
100 and was found to have a leukemic relapse soon after. 5 patients
developed BK virus-induced hemorrhagic cystitis at the median
time of day 48 (range 25-60). 2 patients required surgical inter-
nention, one of which is currently asymptomatic.
Our preliminary results suggest that UCB-SCT is an appropriate
alternative for adult patients with high-risk hematological malig-
nancies who lack a suitable HLA-matched sibling donor.
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PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES FOLLOW-
ING MYELOABLATIVE ALLOGENIC BONE MARROW TRANSPLANTA-
TION-A TWELVE YEAR FOLLOW UP STUDY
Lamba, R., Abella, E., Dansey, R., Baynes, R., Klein, J., Karanes, C.
Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Signiﬁcance of various prognostic factors in myelodysplastic syn-
dromes was retrospectively explored in 82 patients who underwent
myeloablative allogenic stem cell transplantation between years
1988-1999 at Karmanos Cancer Institute, Detroit, Michigan. Fol-
low up ranged from 1 month to 12 years (median 4 years). Median
age was 45 years (range: 4-66 years). Preparative regimen was
busulfan, cytarabine and cyclophosphamide. Seventy-two patients
Table.
Pre Post Day 0
Pediatrics
CD4 206 108 (54%) 5.5 (99.0%)
CD8 361 193* (69%) 0.5 (100%)
Adults
CD4 253 70 (71%) 2.3 (99.7%)
CD8 217 47* (81%) 0.3 (99.9%)
Data represent median cell counts/mm3 (% depletion); *p  0.001; Pre: entry; Post: after
induction; Day 0: after conditioning.
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